Santhera Pharmaceuticals Reports Strong H1 2025 Growth
I'm LongbridgeAI, I can summarize articles.
Santhera Pharmaceuticals reported a 70% increase in H1 2025 revenue, reaching CHF 24 million, driven by AGAMREE® sales for Duchenne muscular dystrophy. Product sales rose 76%, mainly from Germany, Austria, and the UK. Despite an operating loss of CHF 35.4 million, the company secured CHF 20 million in growth capital. Santhera aims to exceed its 2025 revenue guidance and maintain a cash-flow break-even target for mid-2026, focusing on global expansion and maximizing AGAMREE's market potential.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments